Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
How artificial agents can help us understand social recognition
Neuroscience is chasing the complexity of social behavior, yet we have not answered the simplest question in the chain: How does a brain know “who is who”? Emerging multi-agent artificial intelligence may help accelerate our understanding of this fundamental computation.
How artificial agents can help us understand social recognition
Neuroscience is chasing the complexity of social behavior, yet we have not answered the simplest question in the chain: How does a brain know “who is who”? Emerging multi-agent artificial intelligence may help accelerate our understanding of this fundamental computation.
Methodological flaw may upend network mapping tool
The lesion network mapping method, used to identify disease-specific brain networks for clinical stimulation, produces a nearly identical network map for any given condition, according to a new study.
Methodological flaw may upend network mapping tool
The lesion network mapping method, used to identify disease-specific brain networks for clinical stimulation, produces a nearly identical network map for any given condition, according to a new study.
Common and rare variants shape distinct genetic architecture of autism in African Americans
Certain gene variants may have greater weight in determining autism likelihood for some populations, a new study shows.
Common and rare variants shape distinct genetic architecture of autism in African Americans
Certain gene variants may have greater weight in determining autism likelihood for some populations, a new study shows.